Form 4: Entrada Therapeutics CFO Kory James Wentworth Sells Shares
SEC Form 4 Filing
Kory James Wentworth, CFO of Entrada Therapeutics, sold 4,086 shares of common stock at a weighted average price of $12.3067 on March 6, 2024, according to a Form 4 filing with the SEC.
Summary
- On March 6, 2024, Kory James Wentworth, the Chief Financial Officer of Entrada Therapeutics, Inc. (TRDA), sold 4,086 shares of the company's common stock.
- The sale was executed at a weighted average price of $12.3067 per share, with individual transactions occurring between $12.05 and $12.515.
- Following the transaction, Wentworth directly owns 74,170 shares of Entrada Therapeutics.
- The sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 21, 2023.
Sentiment
Score: 5
Explanation: Neutral sentiment as the transaction was pre-planned under a 10b5-1 trading plan and doesn't necessarily reflect a change in the CFO's outlook on the company.
Industry Context
This Form 4 filing is a routine disclosure of insider trading activity. It provides transparency into the transactions of company executives and their holdings in the company. It is important to note that insider sales do not necessarily indicate a negative outlook for the company.
Key Dates
| Date | Description |
|---|---|
| 03/21/2023 | Date of adoption of Rule 10b5-1 trading plan |
| 03/06/2024 | Date of stock sale transaction |
| 03/08/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.